catalyst calendar
INVENTIVA SA · Data as of 2026-10-25
Q4 2026
Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year.Source filing
H1 2027
If the results are positive and subject to regulatory approval, the Company targets the potential new drug application (" NDA ") submission for lanifibranor in the first half of 2027, with a view to potential commercialization in 2028.Source filing
Nov 5
Date: November 5, 2026Source filing
Nov 7
Date: November 7, 2026Source filing